{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:15Z","timestamp":1740144195821,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12282-018-0878-0","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T10:33:01Z","timestamp":1528367581000},"page":"723-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"Omar","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,7]]},"reference":[{"key":"878_CR1","unstructured":"http:\/\/globocan.iarc.fr\n                    \n                  . Accessed 27 Nov 2016."},{"key":"878_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.breast.2016.10.004","volume":"31","author":"G Abdoli","year":"2017","unstructured":"Abdoli G, Bottai M, Sandelin K, Moradi T. Breast cancer diagnosis and mortality by tumor stage and migration background in a nationwide cohort study in Sweden. Breast. 2017;31:57\u201365.","journal-title":"Breast"},{"issue":"1","key":"878_CR3","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1007\/s10549-017-4244-2","volume":"164","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O. Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis. Breast Cancer Res Treat. 2017;164(1):231\u20136.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"878_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.clon.2014.05.002","volume":"26","author":"D Adjogatse","year":"2014","unstructured":"Adjogatse D, Thanopoulou E, Okines A, Thillai K, Tasker F, Johnston SR, et al. Febrile neutropaenia and chemotherapy discontinuation in women aged 70\u00a0years or older receiving adjuvant chemotherapy for early breast cancer. Clin Oncol (R Coll Radiol). 2014;26(11):692\u20136.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"878_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/tbj.12757","volume":"23","author":"F Alarid-Escudero","year":"2017","unstructured":"Alarid-Escudero F, Blaes AH, Kuntz KM. Trade-offs between efficacy and cardiac toxicity of adjuvant chemotherapy in early-stage breast cancer patients: do competing risks matter? Breast J. 2017;23(4):401\u20139.","journal-title":"Breast J"},{"issue":"18","key":"878_CR6","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMe068204","volume":"355","author":"MN Levine","year":"2006","unstructured":"Levine MN, Whelan T. Adjuvant chemotherapy for breast cancer\u201430 years later. N Engl J Med. 2006;355(18):1920\u20132.","journal-title":"N Engl J Med"},{"key":"878_CR7","unstructured":"https:\/\/www.projectdatasphere.org\/projectdatasphere\/html\/home\n                    \n                  . Accessed 7 Oct 2017."},{"issue":"3","key":"878_CR8","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/bcr3179","volume":"14","author":"L Fernandez-Cuesta","year":"2012","unstructured":"Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline\/taxane-based adjuvant therapy: results from the BIG 02\u201398 phase III trial. Breast Cancer Res. 2012;14(3):R70.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"878_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72\u201380.","journal-title":"Lancet Oncol"},{"issue":"29","key":"878_CR10","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2010.28.5437","volume":"29","author":"W Eiermann","year":"2011","unstructured":"Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, et al. Phase III study of doxorubicin\/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011;29(29):3877\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"878_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","volume":"14","author":"BR Bird","year":"2008","unstructured":"Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14(1):14\u201324.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"878_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/14737140.2017.1344099","volume":"17","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O. Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. Expert Rev Anticancer Ther. 2017;17(9):873\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"878_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1586\/14737140.2015.1047766","volume":"15","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, Alorabi M. Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. Expert Rev Anticancer Ther. 2015;15(7):829 \u2013 37.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"878_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","volume":"18","author":"F Viganego","year":"2016","unstructured":"Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016;18(6):52.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"878_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1634\/theoncologist.7-1-65","volume":"7","author":"DL Keefe","year":"2002","unstructured":"Keefe DL. The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern? Oncologist. 2002;7(1):65\u201372.","journal-title":"Oncologist"},{"issue":"2","key":"878_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.radonc.2012.02.008","volume":"103","author":"A Sardaro","year":"2012","unstructured":"Sardaro A, Petruzzelli MF, D\u2019Errico MP, Grimaldi L, Pili G, Portaluri M. Radiation-induced cardiac damage in early left breast cancer patients: Risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol. 2012;103(2):133 \u2013 42.","journal-title":"Radiother Oncol"},{"issue":"7","key":"878_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1517\/14740338.2016.1170115","volume":"15","author":"SH Ahmed","year":"2016","unstructured":"Ahmed SH, Moussa Sherif DE, Fouad Y, Kelany M, Abdel-Rahman O. Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments. Expert Opin Drug Saf. 2016;15(7):911 \u2013 23.","journal-title":"Expert Opin Drug Saf"},{"key":"878_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2017.10.007","volume":"87","author":"E Biganzoli","year":"2017","unstructured":"Biganzoli E, Desmedt C, Fornili M, de Azambuja E, Cornez N, Ries F, et al. Recurrence dynamics of breast cancer according to baseline body mass index. Eur J Cancer. 2017;87:10\u201320.","journal-title":"Eur J Cancer"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-018-0878-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0878-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T19:17:10Z","timestamp":1559848630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-018-0878-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,7]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1007\/s12282-018-0878-0","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"type":"print","value":"1340-6868"},{"type":"electronic","value":"1880-4233"}],"subject":[],"published":{"date-parts":[[2018,6,7]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declared that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this study is based on a publicly available dataset without identifying patient information, informed consent was not needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}